-
-
-
-
-
-
-
Oyster Point Pharma to Report Second Quarter 2021 Financial Results on August 5, 2021
-
-
-
-
-
-
-
Oyster Point Pharma (OYST) Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpinicline) Against SARS-CoV-2 Virus and Variants
-
-
-
-
-
-
-
Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline) Nasal Spray for Patients with Neurotrophic Keratopathy
-
-
-
-
-
-
-
Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface Diseases
-
-
-
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

